IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors
yahoo.com
science
2022-10-18 10:00:00

Â­First patient dosed in IDE397 combination with pemetrexed, representing a novel and potential first-in-class combination in MTAP-deletion tumors

First patient dosed in IDE397 combination with taxane in MTAP-deletion tumors

Clinical strategy for IDE397 also includes combination with AMG 193, Amgen's Phase 1 investigational MTA-cooperative PRMT5 inhibitor in MTAP-deletion tumors

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical program updates for IDE397, an investigational, potential best-in-class, small molecule MAT2A inhibitor being evaluated in an ongoing Phase 1/2 clinical trial (NCT04794699).
